6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hypersensitivity B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
Thoughts O
and O
Behaviors I-OSE_Labeled_AE
in O
Children O
, O
Adolescents O
, O
and O
Adults O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Serotonin B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Abnormal B-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Angle B-OSE_Labeled_AE
Closure I-OSE_Labeled_AE
Glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Activation O
of O
Mania B-OSE_Labeled_AE
/ O
Hypomania B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Discontinuation B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Seizure B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Weight B-OSE_Labeled_AE
and O
Height O
changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Appetite B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
and O
Eosinophilic B-OSE_Labeled_AE
Pneumonia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
: O
nausea O
, O
somnolence O
, O
dry O
mouth O
, O
sweating O
, O
abnormal O
ejaculation O
, O
anorexia O
, O
constipation O
, O
erectile O
dysfunction O
, O
and O
libido O
decreased O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Wyeth O
Pharmaceuticals O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Most O
Common O
Adverse O
Reactions O
The O
most O
commonly O
observed O
adverse O
reactions O
in O
the O
clinical O
study O
database O
in O
Effexor O
XR O
treated O
patients O
in O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
, O
and O
PD B-Not_AE_Candidate
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
were O
: O
nausea B-OSE_Labeled_AE
( O
30.0 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
15.3 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
14.8 O
% O
) O
, O
sweating B-OSE_Labeled_AE
( O
11.4 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
( O
9.9 O
% O
) O
, O
anorexia B-OSE_Labeled_AE
( O
9.8 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
9.3 O
% O
) O
, O
impotence B-OSE_Labeled_AE
( O
5.3 O
% O
) O
and O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
( O
5.1 O
% O
) O
. O

Adverse O
Reactions O
Reported O
as O
Reasons O
for O
Discontinuation O
of O
Treatment O
Combined O
across O
short-term O
, O
placebo-controlled O
premarketing O
studies O
for O
all O
indications O
, O
12 O
% O
of O
the O
3,558 O
patients O
who O
received O
Effexor O
XR O
( O
37.5-225 O
mg O
) O
discontinued O
treatment O
due O
to O
an O
adverse O
experience O
, O
compared O
with O
4 O
% O
of O
the O
2,197 O
placebo-treated O
patients O
in O
those O
studies O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
in O
> O
= O
1 O
% O
of O
the O
Effexor O
XR O
treated O
patients O
in O
the O
short-term O
studies O
( O
up O
to O
12 O
weeks O
) O
across O
indications O
are O
shown O
in O
Table O
7 O
. O

Table O
7 O
: O
Incidence O
( O
% O
) O
of O
Patients O
Reporting O
Adverse O
Reactions O
Leading O
to O
Discontinuation O
in O
Placebo-controlled O
Clinical O
Studies O
( O
up O
to O
12 O
Weeks O
Duration O
) O
Body O
SystemAdverse O
Reaction O
Effexor O
XRn O
= O
3,558 O
Placebon O
= O
2,197 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
1.7 O
0.5 O
Headache B-OSE_Labeled_AE
1.5 O
0.8 O
Digestive B-NonOSE_AE
system I-NonOSE_AE
Nausea B-OSE_Labeled_AE
4.3 O
0.4 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
2.2 O
0.8 O
Insomnia B-OSE_Labeled_AE
2.1 O
0.6 O
Somnolence B-OSE_Labeled_AE
1.7 O
0.3 O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
1.5 O
0.6 O
Sweating B-OSE_Labeled_AE
1.0 O
0.2 O
Common O
Adverse O
Reactions O
in O
Placebo-controlled O
Studies O
The O
number O
of O
patients O
receiving O
multiple O
doses O
of O
Effexor O
XR O
during O
the O
premarketing O
assessment O
for O
each O
approved O
indication O
is O
shown O
in O
Table O
8 O
. O

The O
conditions O
and O
duration O
of O
exposure O
to O
venlafaxine O
in O
all O
development O
programs O
varied O
greatly O
, O
and O
included O
( O
in O
overlapping O
categories O
) O
open O
and O
double-blind O
studies O
, O
uncontrolled O
and O
controlled O
studies O
, O
inpatient O
( O
Effexor O
only O
) O
and O
outpatient O
studies O
, O
fixed-dose O
, O
and O
titration O
studies O
. O

Table O
8 O
: O
Patients O
Receiving O
Effexor O
XR O
in O
Premarketing O
Clinical O
Studies O
Indication O
Effexor O
XR O
MDD B-Not_AE_Candidate
705 O
[ O
note O
: O
In O
addition O
, O
in O
the O
premarketing O
assessment O
of O
Effexor O
, O
multiple O
doses O
were O
administered O
to O
2,897 O
patients O
in O
studies O
for O
MDD B-Not_AE_Candidate
. O
] O

GAD B-Not_AE_Candidate
1,381 O
SAD B-Not_AE_Candidate
819 O
PD B-Not_AE_Candidate
1,314 O
The O
incidences O
of O
common O
adverse O
reactions O
( O
those O
that O
occurred O
in O
> O
= O
2 O
% O
of O
Effexor O
XR O
treated O
patients O
[ O
357 O
MDD B-Not_AE_Candidate
patients O
, O
1,381 O
GAD B-Not_AE_Candidate
patients O
, O
819 O
SAD B-Not_AE_Candidate
patients O
, O
and O
1,001 O
PD B-Not_AE_Candidate
patients O
] O
and O
more O
frequently O
than O
placebo O
) O
in O
Effexor O
XR O
treated O
patients O
in O
short-term O
, O
placebo-controlled O
, O
fixed- O
and O
flexible-dose O
clinical O
studies O
( O
doses O
37.5 O
to O
225 O
mg O
per O
day O
) O
are O
shown O
in O
Table O
9 O
. O

The O
adverse O
reaction O
profile O
did O
not O
differ O
substantially O
between O
the O
different O
patient O
populations O
. O

Table O
9 O
: O
Common O
Adverse O
Reactions O
: O
Percentage O
of O
Patients O
Reporting O
Adverse O
Reactions O
( O
> O
= O
2 O
% O
and O
> O
placebo O
) O
in O
Placebo-controlled O
Studies O
( O
up O
to O
12 O
Weeks O
Duration O
) O
across O
All O
Indications O
Body O
SystemAdverse O
Reaction O
Effexor O
XRn O
= O
3,558 O
Placebon O
= O
2,197 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
12.6 O
7.8 O
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
3.4 O
2.6 O
Palpitation B-OSE_Labeled_AE
2.2 O
2.0 O
Vasodilatation B-OSE_Labeled_AE
3.7 O
1.9 O
Digestive B-NonOSE_AE
system I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
9.8 O
2.6 O
Constipation B-OSE_Labeled_AE
9.3 O
3.4 O
Diarrhea B-OSE_Labeled_AE
7.7 O
7.2 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
14.8 O
5.3 O
Nausea B-OSE_Labeled_AE
30.0 O
11.8 O
Vomiting B-OSE_Labeled_AE
4.3 O
2.7 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
2.9 O
1.4 O
Dizziness B-OSE_Labeled_AE
15.8 O
9.5 O
Insomnia B-OSE_Labeled_AE
17.8 O
9.5 O
Libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
5.1 O
1.6 O
Nervousness B-OSE_Labeled_AE
7.1 O
5.0 O
Paresthesia B-OSE_Labeled_AE
2.4 O
1.4 O
Somnolence B-OSE_Labeled_AE
15.3 O
7.5 O
Tremor B-OSE_Labeled_AE
4.7 O
1.6 O
Respiratory B-NonOSE_AE
system I-NonOSE_AE
Yawn B-OSE_Labeled_AE
3.7 O
0.2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
Sweating B-OSE_Labeled_AE
( O
including O
night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
) O
11.4 O
2.9 O
Special B-NonOSE_AE
senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
4.2 O
1.6 O
Urogenital B-NonOSE_AE
system I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
/orgasm O
( O
men O
) O
[ O
note O
: O
Percentages O
based O
on O
the O
number O
of O
men O
( O
Effexor O
XR O
, O
n O
= O
1,440 O
; O
placebo O
, O
n O
= O
923 O
) O
] O
9.9 O
0.5 O
Anorgasmia B-OSE_Labeled_AE
( O
men O
) O
3.6 O
0.1 O
Anorgasmia B-OSE_Labeled_AE
( O
women O
) O
[ O
note O
: O
Percentages O
based O
on O
the O
number O
of O
women O
( O
Effexor O
XR O
, O
n O
= O
2,118 O
; O
placebo O
, O
n O
= O
1,274 O
) O
] O
2.0 O
0.2 O
Impotence O
( O
men O
) O
5.3 O
1.0 O
Other O
Adverse O
Reactions O
Observed O
in O
Clinical O
Studies O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
- O
Photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
- O
Postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
Digestive B-NonOSE_AE
system I-NonOSE_AE
- O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
bruxism B-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
system I-NonOSE_AE
- O
Ecchymosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
- O
Hypercholesterolemia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
Nervous B-NonOSE_AE
system I-NonOSE_AE
- O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
, O
agitation B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
- O
Urticaria B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
Special B-NonOSE_AE
senses I-NonOSE_AE
- O
Mydriasis B-OSE_Labeled_AE
, O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
Urogenital B-NonOSE_AE
system I-NonOSE_AE
- O
Urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urination B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
menstrual B-OSE_Labeled_AE
disorders O
associated O
with O
increased I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
or O
increased O
irregular O
bleeding O
( O
e.g. O
, O
menorrhagia B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
) O
6.2 O
Vital O
Sign O
Changes O
In O
placebo-controlled O
premarketing O
studies O
, O
there O
were O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
see O
Table O
10 O
) O
. O

Across O
most O
indications O
, O
a O
dose-related O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
systolic O
and O
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
was O
evident O
in O
patients O
treated O
with O
Effexor O
XRs O
. O

Across O
all O
clinical O
studies O
in O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
and O
PD B-Not_AE_Candidate
, O
1.4 O
% O
of O
patients O
in O
the O
Effexor O
XR O
groups O
experienced O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SDBP I-OSE_Labeled_AE
of O
> O
=15 O
mm O
Hg O
along O
with O
a O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg O
, O
compared O
to O
0.9 O
% O
of O
patients O
in O
the O
placebo O
groups O
. O

Similarly O
, O
1 O
% O
of O
patients O
in O
the O
Effexor O
XR O
groups O
experienced O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SSBP I-OSE_Labeled_AE
of O
> O
= O
20 O
mm O
Hg O
with O
a O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg I-OSE_Labeled_AE
, O
compared O
to O
0.3 O
% O
of O
patients O
in O
the O
placebo O
groups O
. O

Table O
10 O
: O
Final O
On-therapy O
Mean B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
From I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Supine I-OSE_Labeled_AE
Systolic I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SSBP I-OSE_Labeled_AE
) O
and O
Diastolic O
( O
SDBP O
) O
Blood O
Pressure O
( O
mm O
Hg O
) O
in O
Placebo-controlled O
Studies O
Effexor O
XR O
Placebo O
Indication O
< O
= O
75 O
mg O
per O
day O
> O
75 O
mg O
per O
day O
( O
Duration O
) O
SSBP O
SDBP O
SSBP O
SDBP O
SSBP O
SDBP O
MDD B-Not_AE_Candidate
( O
8-12 O
weeks O
) O
-0.28 O
0.37 O
2.93 O
3.56 O
-1.08 O
-0.10 O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
-0.28 O
0.02 O
2.40 O
1.68 O
-1.26 O
-0.92 O
( O
6 O
months O
) O
1.27 O
-0.69 O
2.06 O
1.28 O
-1.29 O
-0.74 O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
-0.29 O
-1.26 O
1.18 O
1.34 O
-1.96 O
-1.22 O
( O
6 O
months O
) O
-0.98 O
-0.49 O
2.51 O
1.96 O
-1.84 O
-0.65 O
PD B-Not_AE_Candidate
( O
10-12 O
weeks O
) O
-1.15 O
0.97 O
-0.36 O
0.16 O
-1.29 O
-0.99 O
Effexor O
XR O
treatment O
was O
associated O
with O
sustained O
hypertension B-OSE_Labeled_AE
( O
defined O
as O
treatment-emergent O
Supine B-NonOSE_AE
Diastolic I-NonOSE_AE
Blood I-NonOSE_AE
Pressure I-NonOSE_AE
[ I-NonOSE_AE
SDBP I-NonOSE_AE
] I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mm I-NonOSE_AE
Hg I-NonOSE_AE
and O
> O
= O
10 O
mm O
Hg O
above O
baseline O
for O
three O
consecutive O
on-therapy O
visits O
( O
see O
Table O
11 O
) O
. O

An O
insufficient O
number O
of O
patients O
received O
mean O
doses O
of O
Effexor O
XR O
over O
300 O
mg O
per O
day O
in O
clinical O
studies O
to O
fully O
evaluate O
the O
incidence O
of O
sustained O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
at O
these O
higher O
doses O
. O

Table O
11 O
: O
Sustained O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SDBP I-OSE_Labeled_AE
in O
Effexor O
XR O
Premarketing O
Studies O
Indication O
Dose O
Range O
( O
mg O
per O
day O
) O
Incidence O
( O
% O
) O
MDD B-Not_AE_Candidate
75-375 O
19/705 O
( O
3 O
) O
GAD B-Not_AE_Candidate
37.5-225 O
5/1011 O
( O
0.5 O
) O
SAD B-Not_AE_Candidate
75-225 O
5/771 O
( O
0.6 O
) O
PD B-Not_AE_Candidate
75-225 O
9/973 O
( O
0.9 O
) O
Effexor O
XR O
was O
associated O
with O
mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
compared O
with O
placebo O
in O
premarketing O
placebo-controlled O
studies O
( O
see O
Table O
12 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
, O
5.4 O
) O
] O
. O

Table O
12 O
: O
Approximate O
Mean O
Final O
On-therapy O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Pulse I-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
( O
beats/min O
) O
in O
Effexor O
XR O
Premarketing O
Placebo-controlled O
Studies O
( O
up O
to O
12 O
Weeks O
Duration O
) O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
( O
12 O
weeks O
) O
2 O
1 O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
2 O
< O
1 O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
3 O
1 O
PD B-Not_AE_Candidate
( O
12 O
weeks O
) O
1 O
< O
1 O
6.3 O
Laboratory O
Changes O
Serum O
Cholesterol O
Effexor O
XR O
was O
associated O
with O
mean O
final O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
compared O
with O
mean O
final O
decreases O
for O
placebo O
in O
premarketing O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
and O
PD B-Not_AE_Candidate
clinical O
studies O
( O
Table O
13 O
) O
. O

Table O
13 O
: O
Mean B-OSE_Labeled_AE
Final O
On-therapy O
Changes I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
Concentrations O
( O
mg/dL O
) O
in O
Effexor O
XR O
Premarketing O
Studies O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
( O
12 O
weeks O
) O
+1.5 O
-7.4 O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
+1.0 O
-4.9 O
( O
6 O
months O
) O
+2.3 O
-7.7 O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
+7.9 O
-2.9 O
( O
6 O
months O
) O
+5.6 O
-4.2 O
PD B-Not_AE_Candidate
( O
12 O
weeks O
) O
5.8 O
-3.7 O
Effexor O
XR O
( O
venlafaxine O
hydrochloride O
) O
extended-release O
capsules O
treatment O
for O
up O
to O
12 O
weeks O
in O
premarketing O
placebo-controlled O
trials O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
was O
associated O
with O
a O
mean O
final O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration O
of O
approximately O
1.5 O
mg/dL O
compared O
with O
a O
mean O
final O
decrease O
of O
7.4 O
mg/dL O
for O
placebo O
. O

Effexor O
XR O
treatment O
for O
up O
to O
8 O
weeks O
and O
up O
to O
6 O
months O
in O
premarketing O
placebo-controlled O
GAD B-Not_AE_Candidate
trials O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
of O
approximately O
1.0 O
mg/dL O
and O
2.3 O
mg/dL O
, O
respectively O
while O
placebo O
subjects O
experienced O
mean O
final O
decreases O
of O
4.9 O
mg/dL O
and O
7.7 O
mg/dL O
, O
respectively O
. O

Effexor O
XR O
treatment O
for O
up O
to O
12 O
weeks O
and O
up O
to O
6 O
months O
in O
premarketing O
placebo-controlled O
Social B-Not_AE_Candidate
Anxiety I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
trials O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
of O
approximately O
7.9 O
mg/dL O
and O
5.6 O
mg/dL O
, O
respectively O
, O
compared O
with O
mean O
final O
decreases O
of O
2.9 O
and O
4.2 O
mg/dL O
, O
respectively O
, O
for O
placebo O
. O

Effexor O
XR O
treatment O
for O
up O
to O
12 O
weeks O
in O
premarketing O
placebo-controlled O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
trials O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
of O
approximately O
5.8 O
mg/dL O
compared O
with O
a O
mean O
final O
decrease O
of O
3.7 O
mg/dL O
for O
placebo O
. O

Patients O
treated O
with O
Effexor O
( O
immediate O
release O
) O
for O
at O
least O
3 O
months O
in O
placebo-controlled O
12-month O
extension O
trials O
had O
a O
mean O
final O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
of O
9.1 O
mg/dL O
compared O
with O
a O
decrease O
of O
7.1 O
mg/dL O
among O
placebo-treated O
patients O
. O

This O
increase O
was O
duration O
dependent O
over O
the O
study O
period O
and O
tended O
to O
be O
greater O
with O
higher O
doses O
. O

Clinically O
relevant O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
defined O
as O
1 O
) O
a O
final O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
> O
=50 O
mg/dL O
from O
baseline O
and O
to O
a O
value O
> O
=261 O
mg/dL O
, O
or O
2 O
) O
an O
average O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
> O
=50 O
mg/dL O
from O
baseline O
and O
to O
a O
value O
> O
=261 O
mg/dL O
, O
were O
recorded O
in O
5.3 O
% O
of O
venlafaxine-treated O
patients O
and O
0.0 O
% O
of O
placebo-treated O
patients O
. O

Serum O
Triglycerides O
Effexor O
XR O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
compared O
with O
placebo O
in O
premarketing O
clinical O
studies O
of O
SAD B-Not_AE_Candidate
and O
PD B-Not_AE_Candidate
up O
to O
12 O
weeks O
( O
pooled O
data O
) O
and O
6 O
months O
duration O
( O
Table O
14 O
) O
. O

Table O
14 O
: O
Mean O
Final O
On-therapy O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Triglyceride I-OSE_Labeled_AE
Concentrations O
( O
mg/dL O
) O
in O
Effexor O
XR O
Premarketing O
Studies O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
8.2 O
0.4 O
SAD B-Not_AE_Candidate
( O
6 O
months O
) O
11.8 O
1.8 O
PD B-Not_AE_Candidate
( O
12 O
weeks O
) O
5.9 O
0.9 O
PD B-Not_AE_Candidate
( O
6 O
months O
) O
9.3 O
0.3 O
6.4 O
Pediatric O
Patients O
In O
general O
, O
the O
adverse O
reaction O
profile O
of O
venlafaxine O
( O
in O
placebo-controlled O
clinical O
studies O
) O
in O
children O
and O
adolescents O
( O
ages O
6 O
to O
17 O
) O
was O
similar O
to O
that O
seen O
for O
adults O
. O

As O
with O
adults O
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
were O
observed O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
, O
5.10 O
, O
5.11 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

In O
pediatric O
clinical O
studies O
, O
the O
adverse O
reaction O
, O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
, O
was O
observed O
. O

Particularly O
, O
the O
following O
adverse O
reactions O
were O
observed O
in O
pediatric O
patients O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
myalgia B-OSE_Labeled_AE
. O

6.5 O
Adverse O
Reactions O
Identified O
During O
Postapproval O
Use O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
Effexor O
XR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
: O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
- O
Anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
- O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
( O
including O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
) O
, O
takotsubo B-OSE_Labeled_AE
cardiomyopathy I-OSE_Labeled_AE
Digestive B-NonOSE_AE
system I-NonOSE_AE
- O
Pancreatitis B-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
system I-NonOSE_AE
- O
Mucous B-OSE_Labeled_AE
membrane I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
blood B-OSE_Labeled_AE
dyscrasias I-OSE_Labeled_AE
( O
including O
agranulocytosis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
and O
pancytopenia B-OSE_Labeled_AE
) O
, O
prolonged B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
time I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
- O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
Syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Inappropriate I-OSE_Labeled_AE
Antidiuretic I-OSE_Labeled_AE
Hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
prolactin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
- O
Rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
- O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
serotonergic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
delirium B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
dystonia B-OSE_Labeled_AE
and O
dyskinesia B-OSE_Labeled_AE
) O
, O
impaired B-OSE_Labeled_AE
coordination O
and O
balance I-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
system I-NonOSE_AE
- O
Dyspnea B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
- O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
Special B-NonOSE_AE
senses I-NonOSE_AE
- O
Angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
closure I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O

